42 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 42 of 42 clinical reviews.
Addyi (flibanserin) carries an FDA boxed warning against alcohol. Learn exactly why the interaction is dangerous, what the clinical data show, how long to avoid drinking, and what your prescriber must document before dispensing.
A clinical comparison of flibanserin (Addyi) and bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, including dosing, safety, efficacy data, and how each drug compares to vaginal estrogen and prasterone for related sexual health concerns.
A clinician-reviewed guide to bremelanotide (Vyleesi, PT-141) for hypoactive sexual desire disorder in women, including FDA approval details, dosing, side effects, and how it compares to flibanserin, vaginal estradiol, vaginal DHEA, and compounded testosterone cream.
A clinician-reviewed guide to bupropion for SSRI-induced sexual dysfunction, plus evidence on flibanserin, bremelanotide, vaginal estradiol, and vaginal DHEA (prasterone) for women's sexual health.
Evidence-based review of testosterone therapy for low libido in women, including HSDD diagnosis, trial data from APHRODITE and ADORE, FDA-approved alternatives, and clinical dosing guidance.
A clinician-reviewed guide to compounded oxytocin, flibanserin, bremelanotide, vaginal estradiol, and vaginal DHEA for women's sexual health, including doses, evidence, and how to choose.
A clinician-reviewed guide to compounded testosterone cream for women, covering doses, clinical evidence, comparisons with vaginal estradiol and DHEA, flibanserin, and bremelanotide, and how to get a prescription.
Addyi (flibanserin) costs $800, $1,000/month at brand pricing, but generic flibanserin can drop that to $50, $250/month. Full breakdown of Addyi pricing, insurance coverage, Vyleesi cost comparison, and savings strategies.
A complete breakdown of Vyleesi (bremelanotide) costs in 2025, including cash price, insurance coverage rules, savings programs, and how it compares to Addyi (flibanserin) for treating HSDD in women.
Birth control can lower libido in some women by suppressing androgens and altering SHBG levels. Learn which methods carry the highest risk, what HSDD means, and how HRT or testosterone therapy may help.
A physician-reviewed guide explaining how estrogen, progesterone, and testosterone-based HRT affect female libido, what the clinical evidence shows, and when FDA-approved or off-label treatments are appropriate.
A clinician-reviewed guide to dyspareunia covering genitourinary syndrome of menopause, vaginismus, HSDD, female orgasmic disorder, and treatments including topical estrogen, ospemifene, pelvic floor PT, and flibanserin.
A clinician-reviewed guide to female orgasmic disorder (FOD), covering diagnostic criteria, contributing conditions like HSDD and GSM, and evidence-based treatments including flibanserin, ospemifene, pelvic floor PT, and cognitive behavioral therapy.
A physician-reviewed guide to flibanserin (Addyi), bremelanotide (Vyleesi), vaginal estradiol, vaginal DHEA (prasterone), and compounded testosterone cream for women, with doses, trial data, and candidacy criteria.
A physician-reviewed guide to genitourinary syndrome of menopause (GSM), covering symptoms, diagnostic criteria, FDA-approved treatments, and related conditions including HSDD, dyspareunia, vaginismus, and female orgasmic disorder.
A clinical breakdown of what Vyleesi (bremelanotide) feels like in practice: onset, physical sensations, side effects, and how it compares to hormonal and testosterone-based options for HSDD.
A clinician-reviewed guide to HSDD in women: diagnostic criteria, FDA-approved treatments including flibanserin and bremelanotide, hormonal options, and how related conditions like GSM, vaginismus, and dyspareunia affect sexual desire.
Low libido in women can be a genuine medical condition called HSDD, driven by hormonal, psychological, and physiological causes. Learn when it qualifies as a diagnosable disorder, what tests to request, and which FDA-approved and evidence-supported treatments exist.
A clinician-reviewed guide explaining the hormonal and non-hormonal causes of low libido in women, covering estrogen, testosterone, progesterone, HSDD, FDA-approved treatments including flibanserin and bremelanotide, and evidence-based options for increasing sex drive.
SSRIs and SNRIs frequently cause low libido, delayed orgasm, and vaginal dryness in women. Learn which drugs are worst, which substitutions help, and what non-hormonal and hormonal add-on options are evidence-based for premenopausal, postmenopausal, postpartum, and breast-cancer-survivor patients.
Menopause-related low libido affects up to 55% of postmenopausal women. Learn the hormonal causes, how HSDD is diagnosed, and which FDA-approved and off-label treatments restore sexual desire.
A physician-reviewed guide to ospemifene (Osphena) for dyspareunia and vaginal atrophy, with dosing, safety data, head-to-head comparisons with vaginal estradiol, prasterone, flibanserin, and bremelanotide, and a decision framework for choosing the right therapy.
A clinician-reviewed guide to sexual changes after hysterectomy, covering libido shifts, orgasm changes, genitourinary syndrome of menopause, vaginismus, HSDD, and evidence-based treatment options.
A clinician-reviewed guide to post-SSRI sexual dysfunction in women, covering PSSD mechanisms, HSDD, female orgasmic disorder, GSM overlap, vaginismus, and evidence-based treatments including flibanserin, bupropion, PT-141, and hormone therapy.
A clinician-reviewed guide to postmenopausal sexual health covering genitourinary syndrome of menopause, hormonal and non-hormonal treatments, options after breast cancer, and management on SSRIs/SNRIs.
A clinician-reviewed guide to postpartum, postmenopausal, and premenopausal women's sexual health, including options after breast cancer and on SSRIs/SNRIs. Evidence-based, specific, and actionable.
A clinical comparison of prasterone (Intrarosa) and vaginal estradiol for genitourinary syndrome of menopause, covering mechanism, efficacy data, safety, cost, and how to choose.
A clinician-reviewed guide to sexual dysfunction in premenopausal women, covering causes, treatments, and special populations including postpartum, breast cancer survivors, and women on SSRIs or SNRIs.
Evidence-based PT-141 dosing for women, including starting doses, titration schedules, comparisons with vaginal estradiol and testosterone cream, and safety data from published trials.
PT-141 (bremelanotide) causes nausea in up to 40% of users and transient skin darkening in roughly 1 in 7 women. Learn the mechanisms, management strategies, and how Addyi's alcohol restriction compares.
A clinician-reviewed guide to managing sexual dysfunction, vaginal dryness, low libido, and menopausal symptoms after breast cancer treatment, covering both hormonal and non-hormonal options with current evidence.
Surgical menopause occurs the moment both ovaries are removed, triggering an abrupt hormone drop that is sharper and more medically significant than natural menopause. Learn what to expect, what the evidence says about hormone therapy, and how to protect your long-term health.
Evidence-based guide to testosterone cream dosing for women, including vaginal estradiol cream dosing and PT-141 (bremelanotide) dosing. Learn recommended doses, application sites, monitoring, and safety considerations backed by clinical trials and guidelines.
A clinical review of trazodone's effects on female sexual function, plus a comparison with FDA-approved options including flibanserin, bremelanotide, vaginal estradiol, and vaginal DHEA (prasterone).
A clinician-reviewed guide to vaginal DHEA (prasterone/Intrarosa), covering mechanism, trial data, dosing, and how it compares to vaginal estradiol, compounded testosterone cream, flibanserin, and bremelanotide for women's sexual health.
Evidence-based dosing guide for vaginal estradiol (cream, ring, insert, tablet) plus PT-141 and testosterone cream dosing for women. Reviewed by board-certified physicians.
A physician-reviewed guide to vaginal estradiol covering FDA-approved formulations, dosing, safety data, and comparisons with prasterone, compounded testosterone cream, flibanserin, and bremelanotide for women's sexual health.
A clinical comparison of vaginal estrogen and systemic HRT for menopause symptoms, GSM, and sexual health, including prasterone, Addyi, and Vyleesi, with dosing, safety data, and prescribing guidance.
A comprehensive clinical guide to vaginismus, dyspareunia, HSDD, female orgasmic disorder, and genitourinary syndrome of menopause. Covers diagnosis criteria, FDA-approved treatments, and pelvic floor therapy protocols.
HSDD (Hypoactive Sexual Desire Disorder) is the most common female sexual dysfunction. Learn its hormonal causes, FDA-approved treatments like flibanserin and bremelanotide, and when testosterone therapy applies.
Painful sex after menopause is caused by estrogen loss that thins vaginal tissue, reduces lubrication, and triggers GSM. Local estrogen, systemic HRT, ospemifene, testosterone, and lifestyle changes can restore comfort and desire. Learn which treatment fits your situation.
Evidence-based overview of women's sexual health covering desire, arousal, orgasm, pain disorders, hormonal factors, and treatment options reviewed by board-certified physicians.